Rhythm Pharmaceuticals, Inc.
0 products tracked · names used in filings: Rhythm Pharmaceuticals, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
IMCIVREE: PDUFA target action date (acquired hypothalamic obesity)
Rhythm Pharmaceuticals, Inc. (RYTM); setmelanotide; sNDA; status: set; "…ata from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity -- - 18.8% placebo-adjusted difference in BMI reduction achieved in all patients (N=142) at 52 weeks, including 12 Japanese patients and 10 supplemental patients with acquired hypothalamic obesity -- -- March 20, 2026…"; filed 2026-03-02 · source
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.